Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755205 | 0.85 | OPRD1 (0.43) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL31332725 | 0.84 | CCR2 (0.44) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL4382016 | 0.80 | DRD2 (0.56) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL5790394 | 0.80 | SLC6A3 (0.40) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL18390239 | 0.71 | HSD11B1 (0.55) | OPRM1OPRD1OPRK1 | |
| SCHEMBL20684979 | 0.71 | SLC6A3 (0.45) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL11635882 | 0.70 | DRD2 (0.48) | DRD2 | |
| SCHEMBL16516109 | 0.69 | RAD52 (0.43) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL16516484 | 0.69 | RAD52 (0.43) | SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL16506629 | 0.68 | SLC6A3 (0.44) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441718-B1 | USE OF CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1441718-A4 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050026956-A1 | 3-Aryl-3-pyrrolidinemethanol, 4-aryl-4-piperidinemethanol, or 4-aryl-4-azepinemethanol derivatives; 4-(3-thienyl)- alpha , alpha ,1,1-trimethyl-4-piperidinemethanol; tumors, diabetes, arthritis; autoimmune, genetic, demyelination, and rheumatic disorders; antiinflammatory agents | ENDO PHARMACEUTICALS, INC., A DELAWARE CORPORATION (US) | 2005-02-03 | — | — | US | disclosed |
| US-6825217-B2 | HETEROCYCLIC AMINES SUCH AS 4-(3'-THIENYL)-ALPHA, ALPHA, 1-TRIMETHYL-4-PIPERIDINEMETHANOL AND/OR PRODRUGS, USED AS ANALGESICS FOR PROPHYLAXIS OF NEUROPATHIC PAIN | ENDO PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1441718-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | Endo Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030162811-A1 | Carbinols for the treatment of neuropathic dysfunction | ENDO PHARMACEUTICALS INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003032910-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162811-A1 | Carbinols for the treatment of neuropathic dysfunction | CNR2, CNR1, OPRL1 | SLC6A4 394/4885SLC6A3 311/4885SLC6A2 110/4885 |
| US-20050026956-A1 | 3-Aryl-3-pyrrolidinemethanol, 4-aryl-4-piperidinemethanol, or 4-aryl-4-azepinemethanol derivatives; 4-(3-thienyl)- alpha , alpha ,1,1-trimethyl-4-piperidinemethanol; tumors, diabetes, arthritis; autoimmune, genetic, demyelination, and rheumatic disorders; antiinflammatory agents | PMP22, NAT1, MAG | SLC6A4 2666/4885SLC6A3 2012/4885SLC6A2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.